^Kalda A, Yu L, Oztas E, Chen JF. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. Journal of the Neurological Sciences. October 2006, 248 (1–2): 9–15. PMID 16806272. doi:10.1016/j.jns.2006.05.003.
^Fuxe K, Ferré S, Genedani S, Franco R, Agnati LF. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiology & Behavior. September 2007, 92 (1–2): 210–7. PMID 17572452. doi:10.1016/j.physbeh.2007.05.034.
^Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. Basic Research in Cardiology. May 2008, 103 (3): 203–15. PMID 17999026. doi:10.1007/s00395-007-0687-7.
^Osadchii OE. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovascular Drugs and Therapy. June 2007, 21 (3): 171–94. PMID 17373584. doi:10.1007/s10557-007-6014-6.
^Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chemical Reviews. January 2008, 108 (1): 238–63. PMID 18181659. doi:10.1021/cr0682195.
^Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D. A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Current Pharmaceutical Design. 2008, 14 (15): 1525–52. PMID 18537675. doi:10.2174/138161208784480081.
外部連結
Adenosine Receptors. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. (原始内容存档于2016-10-24).